Memory and Physical Mobility Decline

Assessment:

For this 72-year-old female presenting with memory decline and decreased mobility, a comprehensive assessment is necessary to determine the cause. This evaluation includes:

1. History & Clinical Interview:

   • Onset, progression, and severity of cognitive and physical decline.
   • Any behavioral or personality changes.
   • Past medical history (e.g., hypertension, diabetes, stroke, Parkinson’s).
   • Medication review (checking for polypharmacy, interactions, or side effects).
   • Family history of dementia or neurodegenerative diseases.
   • Functional status (activities of daily living – ADLs, instrumental activities of daily living – IADLs).

2. Physical Examination:

   • Neurological exam: Cranial nerves, motor function, coordination, gait, reflexes.
   • Cognitive screening:
     • Mini-Mental State Examination (MMSE)
     • Montreal Cognitive Assessment (MoCA)
     • Clock Drawing Test
     • Geriatric Depression Scale (to rule out depression-related cognitive impairment)
   • Cardiovascular assessment (checking for signs of vascular disease).

3. Diagnostic Testing:

   • Lab tests:
     • CBC, CMP (electrolyte imbalances, kidney/liver function).
     • Thyroid panel (TSH, T3, T4 – rule out hypothyroidism).
     • Vitamin B12, folate (rule out deficiencies).
     • HbA1c (rule out uncontrolled diabetes).
     • Syphilis/HIV testing (if indicated).
   • Imaging:
     • MRI or CT brain scan (look for signs of stroke, atrophy, or other structural abnormalities).
   • Additional Testing:
     • EEG (if seizures are suspected).
     • PET scan (if Alzheimer’s disease is suspected but unclear from other tests).

Top 3 Differential Diagnoses:

1. Vascular Dementia:

   • Associated with a history of stroke, hypertension, or cardiovascular disease.
   • Presents with stepwise decline in cognition and motor function.
   • MRI may show infarcts or white matter changes.

2. Alzheimer’s Disease (AD):

   • Gradual and progressive memory loss, language deficits, and functional decline.
   • MRI may show hippocampal and cortical atrophy.
   • PET scan may show reduced glucose metabolism in the temporoparietal cortex.

3. Lewy Body Dementia (LBD):

   • Features fluctuating cognition, visual hallucinations, and Parkinsonism.
   • MRI may show relative preservation of hippocampus but generalized atrophy.
   • High sensitivity to antipsychotics.

Initial Treatment Plan:

1. Non-Pharmacologic Management:

• Cognitive stimulation therapy (puzzles, reading, social engagement).
• Physical therapy (if mobility is declining).
• Occupational therapy (assist with ADLs).
• Caregiver education and support (Alzheimer’s Association resources).
• Home safety evaluation (fall prevention, home modifications).
• Nutrition assessment (ensure adequate hydration, protein intake).

2. Pharmacologic Management:

• For suspected Alzheimer’s Disease:
  • Cholinesterase inhibitors: Donepezil (Aricept), Rivastigmine (Exelon), or Galantamine.
  • NMDA receptor antagonist: Memantine (Namenda) for moderate-severe AD.
• For suspected Vascular Dementia:
  • Manage underlying cardiovascular risk factors (antihypertensives, statins, aspirin if indicated).
• For suspected Lewy Body Dementia:
  • Caution with antipsychotics (avoid first-generation antipsychotics, consider low-dose quetiapine if needed).
  • Carbidopa/levodopa if Parkinsonian symptoms are present.

3. Follow-up Plan:

• Reassess in 4–6 weeks to monitor symptoms and treatment response.
• Referral to neurology or geriatrics for further evaluation if needed.
• Consider neuropsychological testing for a more in-depth cognitive assessment.

Would you like me to expand on any specific part?